Effect of various approaches to therapy with statins in high risk patients from the point of view of vascular Endothelium

Kardiologiya

Volumn 49, Issue 5, 2009, Pages 4-10

  Kulev, B D ^a   Ageev, F T ^a  

^a INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

Author keywords

Atorvastatin; Endothelial dysfunction; Hyperlipemia; Ischemic heart disease.

Indexed keywords

ATORVASTATIN; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; PYRROLE DERIVATIVE;

AGED; ARTICLE; BLOOD; BRACHIAL ARTERY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ECHOGRAPHY; FEMALE; FOLLOW UP; HEART MUSCLE ISCHEMIA; HUMAN; HYPERLIPIDEMIA; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; VASODILATATION;

AGED; BRACHIAL ARTERY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPIDS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PYRROLES; RISK FACTORS; TREATMENT OUTCOME; VASODILATION;

EID: 70249092240     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk patients: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22.
2. Nissen S.E., Tuzcu E.M., Schoenhagen P., Brown B.G. et al. REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071-1080. (Pubitemid 38541684)
3. Schwartz G.G., Ollson A.G., Ezekowitz M.D. et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering. (MIRACLE) study Investigators. Effects of Atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACLE study: a randomized controlled trial. JAMA 2001;285:1711-1718. (Pubitemid 32259905)
4. Taneva E., Borucki K., Wiens L. et al. Early effects on endothelial function of atorvastatin 40 mg twice daily and its withdrawal. Am J Cardiol 2006; 97: 1002-1006.
5. Glasziou P.P., Simes R.J., Hall J., Donaldson C. Design of a cost-effectiveness study within a randomized trial: the LIPID Trial for Secondary Prevention of IHD. Long-term Intervention with Pravastatin in Ischemic Heart disease. Control Clin Trials 1997;18:464-476. (Pubitemid 28059886)
6. Simons LA., Sullivan D., Simons J., Celermajer D.S. Effect of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endohelial function in patients with severe primary hypercholesterolaemia. Atherosclerosis 1998;137:197-203. (Pubitemid 28175392)
7. Marchesi S., Lupatteli G., Siepi D. et al. Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovasc Pharmacol 2000; 36: 617-621.
8. Hosokawa S., Hiasa Y., Tomokane T. et al. The effects of atorvastatin on coronary endothelial function in patients with recent myocardial infarction. Clin Cardiol 2006;29:357-362. (Pubitemid 44267055)
9. Souza-Costa D.C., Sandrim V.C., Lopes L.F. et al. Antiinflammatory effects of atorvastatin: modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene. Atherosclerosis 2007;193:438-444. (Pubitemid 47058109)
10. Laufs U., La Fata V., Plutzky J., Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-1135. (Pubitemid 28152885)
11. Laufs U., Liao J.K. Post-tanscriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998; 273: 24 266-24 271.
12. Laufs U., Marra D., Node K., Liao J.K. 3-Hydroxy-3-methylglutarylCoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27 (Kip 1). J Biol Chem 1999; 274: 21 926-21 931.
13. Aikawa M., Rabkin E., Sugiyama S. et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001;103:276-283. (Pubitemid 32095415)
14. Huhle G., Abletshauser C., Mayer N. et al. Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor. Thromb Res 1999;95:229-234. (Pubitemid 29428154)
15. Fukumoto Y., Libby P., Rabkin E. et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation 2001;103:993-999. (Pubitemid 32183806)
16. Feinstein S.B. Contrast ultrasound imaging of the carotid artery vasa vasorum and atherosclerotic plaque neovascularization. J Am Coll Cardiol 2006; 48: 236-243.
17. Stoll L.L., McCormick M.L., Denning G.M., Weintraub NL. Antioxidant effects of statins. Drugs Today (Bare) 2004; 40: 975-990.
18. Ridker P.M., Rifai N., Pfeffer MA. et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Invest Circul 1998;98:839-844. (Pubitemid 28397432)
19. Arnaud C., Braunersreuther V., Mach F. Toward immunomodulatory and anti-inflammatory properties of statins. Trends Cardiovasc Med 2005;15:202-206. (Pubitemid 41338006)
20. Wassmann S., FaulA., Hennen B. et al. Rapid effect of 3-hydroxy3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res 2003 31; 93: 98-103.
21. Taneva E., Borucki K., Wiens L. et al. Early effects on endothelial function of atorvastatin 40 mg twice daily and its withdrawal. Am J Cardiol 2006; 97: 1002-1006.
22. Igarashi J., Miyoshi M., Hashimoto T. et al. Statins induce SlPl receptors and enhance endothelial nitric oxide production in response to high-density lipoproteins. Br J Pharmacol 2007;150:470-479. (Pubitemid 46280654)
23. Yildiz A., Cakar M.A., Baskurt M. et al. The effects of atorvastatin therapy on endothelial function in patients with coronary artery disease. Cardiovasc Ultrasound 2007; 5: 51.
24. Smilde T.J., van Wissen S., Wollersheim H. et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomised, double-blind trial. Lancet 2001; 357: 574-575.
25. Cannon C.P., Braunwald E., McCabe C.H. et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1562-1564.
26. Pedersen T.R., Faergeman O., Kastelein J.J. et al. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: A randomized controlled trial. JAMA 2005; 294: 2492-2494.
27. Ridker P.M., Morrow D.A., Rose L.M. et al. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l:an analysis of the PROVE-IT TIMI22 trial. J Am Coll Cardiol 2005;45:1644-1648. (Pubitemid 40704500)
28. Kureishi Y., Luo Z, Shiojima I. et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2001;7:129. (Pubitemid 32095653)
29. Feron O., Dessy C., Desager J. P., Balligand J.L. Hydroxymethylglutaryl- coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001; 103: 2-4.
30. Guthikonda S., Sinkey C.A., Haynes W.G. What is the most appropriate methodology for detection of conduit artery endothelial dysfunction? Arterioscler Thromb Vase Biol 2007;27:1172-1176. (Pubitemid 46641975)
31. Doshi S.N., Naka K.K., Payne N. et al. Flow-mediated dilatation following wrist and upper arm occlusion in humans: the contribution of nitric oxide. Clin Sei (Lond) 2001;101:629-635. (Pubitemid 33135344)
32. Gokce N., Keaney J.F. Jr., Hunter L.M. et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 2003;41:1769-1775. (Pubitemid 36584251)
33. Huang A.L., Silver A.E., Shvenke E. et al. Predictive value of reactive hyperemia for cardiovascular events in patients with peripheral arterial disease undergoing vascular surgery. Arterioscler Thromb Vase Biol 2007; 27: 2065-2067.